Aleniglipron
ACCESS
Gasherbrum Bio, Inc · Phase 2 · Completed · Enrollment 230
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Cohort 1 | n/r | n/r | n/r | n/r | n/r |
| Cohort 2 | n/r | n/r | n/r | n/r | n/r |
| Cohort 3 | n/r | n/r | n/r | n/r | n/r |
| Cohort 1 OLE | n/r | n/r | n/r | n/r | n/r |
| Cohort 2 OLE | n/r | n/r | n/r | n/r | n/r |
| Cohort 3 OLE | n/r | n/r | n/r | n/r | n/r |
| Cohort 4 OLE | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.